Search

everythinglearnresearchcommunity

for

Search:↓

User on 5th week of Pyrilutamide and oral Minoxidil, no hair loss improvement yet. Others suggest waiting 3 months for results.

PP405 is expected to be on the market between 2027 and 2030, with phase 3 trials starting in 2026. There is skepticism about its fast-tracking due to its cosmetic nature, and it may appear on the gray market sooner.

Chime Biologics and Hope Medicine are speeding up the launch of a first-in-class antibody drug, HMI-115, for endometriosis and androgenic alopecia. The treatment involves a series of subcutaneous injections, has shown promising results in phase 1, and continues to promote hair regrowth even after the treatment is stopped.

A 35-year-old had a hair transplant with 3,153 grafts at HLC Ankara, experiencing some pain and numbness but pleased with the density and results. The procedure cost $10,000, and the user has been using finasteride for over 13 years.

People discussing their experiences with hair loss treatments found that switching from finasteride (Fin) to dutasteride (Dut) often resulted in improved hair thickness and health, despite some experiencing side effects or shedding phases. Some users switched due to diminishing results with Fin, while others were curious about the potential for better outcomes with Dut.

People using finasteride and minoxidil for hair loss experience multiple shedding phases, with some reporting regrowth and improved self-esteem, while others struggle with ongoing hair loss. Despite the challenges, many find the treatments worthwhile, though results vary.

The user has been using a combination of 0.3% topical finasteride, minoxidil, ketoconazole, and microneedling once a week for two months with positive results and no side effects. They apply the treatment daily using a spray and have short hair, which makes application easier.

The conversation discusses disappointment over only receiving a financial report from Cassiopea instead of trial results for Breezula/CB-03-01, a hair loss treatment. However, there is optimism as the company is advancing Breezula into Phase III trials for men, starting trials for women, and submitting an NDA for their acne product, Winlevi.

A 25-year-old experienced significant hair regrowth using 5% minoxidil for 9.5 months despite an initial shed and a second shedding phase lasting 3.5 months. They encourage others to persist with minoxidil treatment through shedding as regrowth can occur.

The user shared their hair regrowth journey using topical minoxidil and finasteride since December 2021, experiencing shedding phases but ultimately achieving positive results by sticking with the treatment. They advise others to continue with their regimen despite shedding, as it can be a sign of the treatment working.

The user has been using finasteride and minoxidil for over 7 years, switched to dutasteride 3 years ago, and is satisfied with the results. They experienced no noticeable side effects and use minoxidil on their hairline and temples.

User shared 2-year hair loss progress using finasteride 3 times a week and 5 mg oral minoxidil daily. Another user praised the results as a complete recovery.

Ketoconazole 2% shampoo stopped a user's severe hair shedding after just two uses, a result not achieved by finasteride or oral minoxidil. Some users suggest the shampoo's anti-androgenic properties may help with hair loss, while others think the shedding might have stopped naturally or due to the end of a shedding phase.

Current treatments like finasteride, minoxidil, and derma rolling are considered the best for hair loss, while new treatments such as GT20029, PP405, and others are in various trial phases with results expected in the coming years. There is cautious optimism about the affordability and effectiveness of these upcoming treatments.

GT20029 and PP405 are discussed as potential alternatives or complements to finasteride for hair loss treatment. GT20029 is entering phase 3 trials, while PP405 is seen as promising for regrowing hair and possibly eliminating the need for other treatments.

PP405 shows promise for hair regrowth by manipulating stem cell characteristics and lactate dehydrogenase, with Phase 2a trials pending. Google Ventures' $15M investment suggests confidence, but results and market availability remain uncertain.

Discouragement regarding Pyrilutamide, a drug in development for hair loss, and the potential side effects of Finasteride. People discussed anecdotal experiences with Pyrilutamide as well as suggestions to wait out Phase 3 trials before making any conclusions.

A woman underwent a hair transplant in Istanbul, receiving 3,000 grafts, and is pleased with the natural-looking results one year later. The experience included a 5-star hotel stay, PRP session, laser treatment, and detailed aftercare, leading to improved hair density and confidence.

The user has been using a regimen of dutasteride (DUT) and topical minoxidil (1ml once a day) for six months, resulting in hair regrowth and increased thickness. The user reports no side effects and mentions that the shedding phase lasted about a month.

PP405 is considered a promising potential cure for hair loss, with phase 2 trial results expected in February 2025. Hair cloning is also discussed as a potential ultimate solution, despite significant scientific challenges.

The user shared a 15-month hair loss treatment update using Dutasteride (0.5mg/day), Minoxidil (5% foam twice daily), Nizoral (1% every 3 days), and a 1.5mm derma roller (twice a month), along with a multivitamin, exercise, low sugar diet, hydration, and consistent sleep. They started seeing results after 6-9 months, with significant improvement at the 1-year mark, and apply Minoxidil the day after derma rolling.

User shared progress on hair regrowth using 1.25 mg finasteride daily, 5% minoxidil, and a 1.5 mm dermaroller twice a week, with no side effects. Users discussed shedding phases, application methods, and the necessity of continuous treatment to maintain results.

Pyrilutamide, a potentially effective hair loss treatment; other topical treatments like RU58841 and CB-03-01 that may have fewer side effects than Pyrilutamide; and the Phase 3 clinical trials of Pyrilutamide, which is likely to be approved by the FDA soon.

Kintor is accused of using fake pictures to promote their product, Pyrilutamide (KX826), which failed Phase 3 trials. Users express disappointment and note similar false advertising has occurred with finasteride and minoxidil.

The conversation is about when GT20029, a hair loss treatment, might be available on the grey market, with users discussing the challenges of compounding it and speculating it might be available after phase 2 results, similar to pyri. Specific treatments mentioned are pyri, RU58841, and GT20029.

The user experienced hair regrowth using finasteride every other day and topical minoxidil but is currently going through a shedding phase. Despite the shedding, progress is evident, and users suggest patience and possibly adding microneedling to improve results.

The user has been using dutasteride twice a week for 8 months and oral minoxidil for 3 months but is experiencing increased hair thinning. Many recommend taking dutasteride daily for improved results.

The user experienced significant hair regrowth and healthier hair after two months of using oral finasteride, minoxidil, and biotin, despite an initial shedding phase. They reported no negative effects on their beard or facial bloating and were surprised by the quick results.

The conversation discusses hair shedding after switching from finasteride to dutasteride for hair loss treatment. Users suggest that shedding is a common and temporary phase, with results expected in about 6 to 8 months.

Finasteride can cause scalp itch and inflammation, possibly due to DHT changes, but these effects are often temporary and part of the shedding phase. Consistent use of finasteride may show results after 6 months, with potential hair regrowth and slowed hair loss.